Sign in →

Epic Test Code LAB475 Lamotrigine, Serum

Additional Codes

MML Code: LAMO

LIS Code: LMTG

NY State Approved

Yes

Performing Laboratory

Mayo Clinic Laboratories in Rochester

Reporting Name

Lamotrigine, S

Method Name

Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)

Specimen Stability Information

Specimen Type Temperature Time Special Container
Serum Refrigerated (preferred) 28 days
  Ambient  28 days
  Frozen  28 days


Specimen Required


Supplies: Sarstedt Aliquot Tube, 5 mL (T914)

Collection Container/Tube:

Preferred: Red top

Acceptable: Serum gel

Submission Container/Tube: Plastic vial

Specimen Volume: 1 mL

Collection Instructions:

1. Collect blood immediately before next scheduled dose.

2. For sustained-release formulations only, collect blood a minimum of 12 hours after last dose.

3. Centrifuge within 2 hours of collection

4. For red-top tubes, immediately aliquot serum into a plastic vial.

5. For serum gel tubes, aliquot serum into a plastic vial within 24 hours of collection.


Specimen Type

Serum

Specimen Minimum Volume

0.5 mL

Reference Values

Patients receiving therapeutic doses usually have lamotrigine concentrations of 3.0-15.0 mcg/mL.

Report Available

Same day/1 to 2 days

Day(s) Performed

Monday through Sunday

CPT Code Information

80175

Reject Due To

Gross hemolysis OK
Gross lipemia OK
Gross icterus OK
 

Useful For

Monitoring serum concentration of lamotrigine

 

Assessing compliance

 

Adjusting lamotrigine dose in patients receiving other anticonvulsant drugs that interact pharmacokinetically with lamotrigine

Clinical Information

Lamotrigine (Lamictal) is approved for therapy of bipolar I disorder and a wide variety of seizure disorders including Lennox-Gastaut syndrome, primary generalized tonic-clonic seizures, and partial seizures. Its many off-label uses include treatment of migraine, trigeminal neuralgia, and treatment-refractory depression. Lamotrigine inhibits glutamate release (an excitatory amino acid) and voltage-sensitive sodium channels to stabilize neuronal membranes; it also weakly inhibits the 5-HT3 (serotonin) receptor.

 

Lamotrigine oral bioavailability is very high (approximately 98%). The drug is metabolized by glucuronic acid conjugation to inactive metabolites. The half-life is 25 to 33 hours in adults but decreases with concurrent use of phenytoin or carbamazepine (13-14 hours) and increases with concomitant valproic acid therapy (59-70 hours), kidney dysfunction, or hepatic impairment. The therapeutic range is relatively wide, 3 to 15 mcg/mL for most individuals. Common adverse effects are dizziness, ataxia, blurred or double vision, nausea, or vomiting.

Interpretation

The serum concentration should be interpreted in the context of the patient's clinical response and may provide useful information in patients showing poor response, noncompliance, or adverse effects, particularly when lamotrigine is coadministered with other anticonvulsant drugs.

 

While most patients show response to the drug when the trough concentration is in the range of 3.0 to 15.0 mcg/mL and show signs of toxicity when the peak serum concentration is greater than 20 mcg/mL, some patients can tolerate peak concentrations as high as 70 mcg/mL.

Cautions

Serum separator tube is acceptable but serum must be removed from gel within 24 hours of collection.

Specimen Retention Time

14 days

Forms

If not ordering electronically, complete, print, and send 1 of the following forms with the specimen:

-Neurology Specialty Testing Client Test Request (T732)

-General Request (T239)

-Therapeutics Test Request (T831)